-
Fierce Biotech6 months ago
Genentech antibody fails to boost muscle in rare diseases, raising questions for obesity trial
Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle growth, raising questions about whether the molecule...
-
STAT News – Biotech6 months agoSTAT+: Pharmalittle: We’re reading about TrumpRx expectations, a high-dose version of Wegovy, and more
And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to...
-
Uncategorized6 months agoThis week in Drug Discovery (16 – 20 March)
News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW. This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been...
-
Endpoints News6 months ago
Novo Holdings CEO discusses investments, geopolitics and China
The assets managed by Novo Holdings, the controlling shareholder of Novo Nordisk, fell by some 35% last year. But that doesn’t mean it will rein in...
-
Uncategorized6 months agoEvotec to receive $10m as kidney cancer trial launches
Evotec will receive a $10 million milestone payment as a kidney cancer trial has got underway. Bristol Myers Squibb has launched its Phase I clinical study evaluating CELMoD agent BMS-986506, a cereblon E3...
-
Endpoints News6 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar target,...
-
BioPharma Dive – AI / Data6 months agoRhythm obesity drug wins broader use from FDA
Imcivree’s clearance in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to be worth more than $1 billion.
-
STAT News – Biotech6 months agoSTAT+: U.K. to take another look at cost-effectiveness of Alzheimer’s drugs
LONDON — U.K. health officials on Friday said they had reopened a review of two new Alzheimer’s therapies after previously finding they did not provide good...
-
Uncategorized6 months agoLilly wins appeal for donanemab, drug to be reconsidered for NHS
Eli Lilly’s appeal against guidance which did not recommend donanemab has been upheld, forcing authorities to reconsider the drug for NHS use. The National Institute for...
-
Endpoints News6 months ago
Idorsia looks for another CEO — again; Former Jazz exec makes a comeback
→ Srishti Gupta took over as CEO of Idorsia last summer, but the job is open again as chairman Jean-Paul Clozel kicks off another search. Idorsia’s...
FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
Deep dive: Psychedelics back on FDA’s doorstep
‘Patients are not a renewable resource’: Rethinking rare disease R&D
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
